Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03508726
Recruitment Status : Recruiting
First Posted : April 26, 2018
Last Update Posted : July 22, 2019
Sponsor:
Collaborator:
University of Iowa
Information provided by (Responsible Party):
Varun Monga, University of Iowa

Tracking Information
First Submitted Date  ICMJE April 13, 2018
First Posted Date  ICMJE April 26, 2018
Last Update Posted Date July 22, 2019
Actual Study Start Date  ICMJE June 27, 2019
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 29, 2019)
  • Incidence of dose limiting toxicities (DLTs) using CTCAE, Version 4.0 [ Time Frame: Start of treatment up to 4 weeks after the last ascorbate infusion ]
    To examine the toxicity related to the therapy by measuring the number attributed adverse event (definite, probable or possible) according to CTCAE version 4.0.
  • Tumor response as assessed by pathological complete response rates (pCR) [ Time Frame: Start of treatment up to 6 weeks after the last ascorbate infusion ]
    For this study, pCR will be defined as ≥ 95% tumor necrosis following concurrent radiation therapy and ascorbate.
Original Primary Outcome Measures  ICMJE
 (submitted: April 23, 2018)
  • Toxicity [ Time Frame: Start of treatment up to 4 weeks after the last ascorbate infusion ]
    To examine the toxicity related to the therapy by measuring the number attributed adverse event (definite, probable or possible) according to CTCAE version 4.0.
  • Tumor response as assessed by pathological complete response rates (pCR) [ Time Frame: Start of treatment up to 6 weeks after the last ascorbate infusion ]
    For this study, pCR will be defined as ≥ 95% tumor necrosis following concurrent radiation therapy and ascorbate.
Change History Complete list of historical versions of study NCT03508726 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 23, 2018)
  • Disease progression as measured by time to disease progression (TTP) [ Time Frame: Enrollment or start of treatment up to 2 years following end of treatment ]
    Time to disease progression (TTP) is defined as the time from enrollment until objective tumor progression including local and distant recurrences.
  • Overall response rate as measured by RECIST 1.1 [ Time Frame: Enrollment or start of treatment up to 2 years following end of treatment ]
    Overall response rate (ORR) preoperative as measured by RECIST 1.1 or a later tool for monitoring disease progression.
  • Overall survival estimated using the Kaplan-Meier Method [ Time Frame: Enrollment or start of treatment up to 2 years following end of treatment ]
    Overall survival (OS) rate data gathered through passive chart review, phone call or scheduled follow-up visit and estimated using the Kaplan-Meier Method.
  • Skin toxicity [ Time Frame: Within two years following end of treatment ]
    Pathologist to grade radiation related skin toxicity overlying the tumor as compared to historical controls. Binomial exact tests will be utilized to identify differences in wound complication and Grade 3-4 dermatitis rates compared to historical controls.
  • Labile iron [ Time Frame: Within two years following end of treatment ]
    To measure labile iron using T2* imaging sequence on MRI pre and post ascorbate treatments and compare with serum iron measurements
  • Evaluate diffusion weighted imaging sequences [ Time Frame: Within two years following end of treatment ]
    To evaluate diffusion weighted imaging sequences on MRI in pre and post treatment tumors and correlate it with necrosis and survival
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas
Official Title  ICMJE Phase 1b/2 Neoadjuvant High Dose Ascorbate With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas of Extremity, Trunk and Retroperitoneum
Brief Summary This is a single-arm open-label phase Ib/II clinical study assessing the efficacy of concurrent high dose ascorbate in combination with radiotherapy in patients with locally advanced, resectable, high grade sarcomas.
Detailed Description

Phase Ib:

The phase Ib portion of this study is to ensure the safety and tolerability of high dose ascorbate in combination with external beam radiation therapy (EBRT) as assessed by incidence of dose-limiting toxicities (DLT). EBRT will be given at the standard dose for resectable soft tissue sarcomas according to the NCCN sarcoma guidelines.2 Patients will receive 50 Gy over 5 weeks, during which time they will be receiving three times a week IV high dose ascorbate. IV ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation to allow for adequate tissue healing and resolution of acute toxicities.

Phase 2:

The phase 2 part of the study will provide an estimate of the relative treatment effect of pharmacological ascorbate in combination with preoperative EBRT in subjects with locally advanced, resectable, extremity, trunk or retroperitoneal high grade sarcomas, as measured by pathological response rates.

As above, patients will receive the first dose of pharmacological ascorbate intravenously on day 1 of week 1 provided no reactions are seen to the test dose. This will be followed by 3 times a week dosing at Dose 0 until completion of EBRT. Standard doses of radiation for resectable soft tissue sarcomas according to the NCCN sarcoma guidelines will be administered.2 Patients will receive preoperative radiation at a dose of 50 Gy over 5 weeks starting on week 1 day 1. Subjects will be followed either by clinic visit or phone contact every 12 weeks for approximately 24 months after the end of the treatment phase, at which time the initial survival data and disease recurrence will be assessed.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Soft Tissue Sarcoma
Intervention  ICMJE Drug: Ascorbate

Phase 1 dose escalation:

75gm IV three times a week

Phase II portion:

75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV

Other Names:
  • Ascorbic Acid
  • Vitamin C
  • Pharmacological ascorbate
Study Arms  ICMJE Experimental: Phase I dose escalation/Phase II portion

Phase 1 dose escalation:

Patients will receive radiation therapy over 5 weeks, during which time they will be receiving ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.

Phase II portion:

Patients will receive radiation therapy over 5 weeks, during which time they will be receiving intravenous (IV) ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.

Intervention: Drug: Ascorbate
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 23, 2018)
25
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2022
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject or subject's legally acceptable representative has provided informed consent.
  2. Histologically confirmed diagnosis of locally advanced STS of extremity or retroperitoneum that is unresectable with clear wide margins, for which preoperative radiotherapy is considered appropriate.

    • Resectable stage IIB, III, and IV disease that are not suitable for surgically resection alone due to inability to achieve clear margins.
    • Including metastatic (stage IV) disease for which radiotherapy and surgical resection are indicated.
  3. Patients with locally recurrent sarcoma after surgery alone are eligible for enrollment if other inclusion criteria are met.
  4. Patients do not have histologic subtypes: GIST, Desmoid, Ewing sarcoma, bone sarcomas and Kaposi sarcoma.
  5. Age ≥18 years.
  6. Patients with non-melanomatous skin cancer, in situ carcinoma, or low-risk prostate cancer can be enrolled.
  7. ECOG performance status </=1.
  8. Tolerate one test dose (15g) of ascorbate.
  9. Patient must have measurable disease:

    • Tumor size at least >/= 5 cm in the longest diameter as measured by CT scan or MRI for which radiation is feasible and indicated.

Exclusion Criteria:

  1. Inadequate organ function within 21 days of Day 1 of study as defined by:

    • Hemoglobin < 9.0 g/dL
    • Absolute neutrophil count (ANC) </= 1500 per mm3
    • Platelet count </= 100,000 per mm3
    • Total bilirubin >/= 1.5 × ULN. Subjects with direct bilirubin < ULN with total bilirubin levels > 1.5 X ULN will not be excluded.
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × ULN
    • Alkaline phosphatase > 2.5 × ULN
    • PT (or INR) and PTT (or aPTT) >/= 1.5 × ULN
    • Creatinine > 2.0 × ULN
  2. G6PD (glucose-6-phosphate dehydrogenase) deficiency.
  3. Prior history of symptomatic oxalate kidney stones within the last year.
  4. Prior radiation therapy in excess of 20 Gy to the site of the current diagnosis of sarcoma. No overlap with prior radiation fields in excess of 20 Gy is allowed.
  5. Prior history of receiving pharmacological ascorbate.
  6. Patients actively receiving insulin therapy or needing daily fingerstick for glucose monitoring.
  7. Concurrent, clinically significant, active malignancies within two years of study enrollment.
  8. Female subjects who are pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment.
  9. Female subjects of childbearing potential or male subjects who are unwilling to use 2 highly effective methods of contraception during study treatment and through 3 months after the last dose of study treatment.
  10. Currently receiving treatment in another invasive investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s).
  11. Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide. High dose ascorbic acid may affect urine acidification and, as a result, may affect clearance rates of these drugs.
  12. Known CNS disease, except for treated brain metastasis: Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded.
  13. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ascorbate.
  14. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  15. Known HIV-positive and hepatitis B & C individuals. High-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs.
  16. Patients who are on warfarin and cannot have a drug substitution or who decline the drug substitution.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Varun Monga, MBBS 319-384-9497 varun-monga@uiowa.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03508726
Other Study ID Numbers  ICMJE 201901810
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Varun Monga, University of Iowa
Study Sponsor  ICMJE Varun Monga
Collaborators  ICMJE University of Iowa
Investigators  ICMJE
Principal Investigator: Varun Monga, MBBS University of Iowa
PRS Account University of Iowa
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP